MTOR and breast carcinoma: Acquiring the resistance to mTOR inhibitors (most commonly rapamycin and its derivates) was detected in various tumours' models in vitro as well as in vivo in patients suffering from such conditions as i.a. breast cancers, gliomas 3,4,31.